In a report released on January 5, Thomas Shrader from BTIG maintained a Buy rating on Coya Therapeutics, Inc. (COYA – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $6.82.
Shrader covers the Healthcare sector, focusing on stocks such as Aldeyra Therapeutics, Alector, and Acumen Pharmaceuticals. According to TipRanks, Shrader has an average return of 5.1% and a 40.30% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Coya Therapeutics, Inc. with a $13.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $8.00 and a one-year low of $3.21. Currently, Coya Therapeutics, Inc. has an average volume of 49.65K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Coya Therapeutics, Inc. (COYA) Company Description:
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Read More on COYA:
